12 February 2026

The Manager Market Announcements Office

Australian Securities Exchange

Dear Manager,

NOTICE OF EXTRAORDINARY GENERAL MEETING

The following documents were sent to Shareholders today in relation to the Extraordinary General Meeting of OncoSil Medical Limited (ASX:OSL) to be held on Thursday, 12 March 2026 at 10:00 am (AEDT):

1. Access Letter to Shareholders
2. Notice of Meeting
3. Proxy Form

This announcement was authorised to be given to ASX by the Board of Directors of OncoSil Medical Limited.

Yours sincerely,

Mr Timothy Luscombe

Company Secretary

12 February 2026

OncoSil Medical Limited

Extraordinary General Meeting

Dear Shareholder,

You are invited to attend the **Extraordinary** General Meeting (**EGM**) of OncoSil Medical Limited (ASX: OSL) (**OncoSil** or the **Company**), which will be held as a virtual meeting on Thursday, 12 March 2026, commencing 10.00 am (AEDT).

The Notice of Meeting can be viewed and downloaded from "ASX Announcements" section of OncoSil's website at www.oncosil.com/investors.

A copy of your personalised proxy form is enclosed for your convenience. If you are unable to attend the EGM, Shareholders are encouraged to complete and lodge their proxies online or otherwise in accordance with the instructions set out in the proxy form and the Notice.

The Notice is important and should be read in its entirety. If you have any questions regarding the matters set out in the Notice, please contact OncoSil, your stockbroker or other professional adviser.

How to submit your vote in advance of the meeting

To be valid, your proxy form (and any power of attorney under which it is signed) must be received by the Share Registry by 10:00 am (AEDT) on Tuesday, 10 March 2026.

To submit your proxy:

1. Vote online at https://www.votingonline.com.au/oslegm26;
2. Post to Boardroom Pty Limited, GPO Box 3993, Sydney NSW 2001 Australia; or
3. Fax to +61 2 9290 9655.

We look forward to your participation at the EGM and thank you for your continued support.

Yours sincerely,

Dr Thomas Duthy
Chair

ONCOSIL MEDICAL LIMITED

ACN 113 824 141

NOTICE OF EXTRAORDINARY GENERAL MEETING

TIME: 10.00 (AEDT)

DATE: Thursday, 12 March 2026

PLACE: The Extraordinary General Meeting will be held as a virtual meeting at

https://meetings.lumiconnect.com/300-972-839-431

THIS NOTICE OF EXTRAORDINARY GENERAL MEETING SHOULD BE READ IN ITS ENTIRETY. IF SHAREHOLDERS ARE IN DOUBT AS TO HOW THEY SHOULD VOTE, THEY SHOULD SEEK ADVICE FROM THEIR PROFESSIONAL ADVISERS.

SHOULD YOU WISH TO DISCUSS THE MATTERS IN THIS NOTICE OF EXTRAORDINARY GENERAL MEETING PLEASE DO NOT HESITATE TO CONTACT THE COMPANY SECRETARY ON (02) 9223 3344.

CONTENTS PAGE

Time and Place of Meeting and How to Vote	1
Letter from the Chairman	3
Notice of Extraordinary General Meeting	4
Explanatory Memorandum	8

TIME AND PLACE OF MEETING AND HOW TO VOTE

VENUE

Notice is hereby given that the Extraordinary General Meeting of the shareholders of OncoSil Medical Limited ACN 113 824 141 (**Company**) will be held as a virtual meeting at 10.00am (AEDT) on Thursday, 12 March 2026 (**EGM**).

YOUR VOTE IS IMPORTANT

The business of the EGM affects your shareholding, and your vote is important.

VOTING BY PROXY

To vote by proxy, please complete and sign the enclosed Proxy Form and return by:

(a) post to Boardroom Pty Limited, GPO Box 3993, Sydney NSW; or

(b) facsimile to Boardroom Pty Limited, on facsimile number +61 2 9279 9664, or

(c) in person to Boardroom Pty Limited at Level 8, 210 George Street, Sydney, NSW, or

(d) online at: https://www.votingonline.com.au/oslegm26.

so that it is received not later than 10.00am (AEDT) on Tuesday, 10 March 2026.

Proxy forms received later than this time will be invalid.

In accordance with section 249L of the Corporations Act, members are advised that:

- each member has a right to appoint a proxy;
- the proxy need not be a member of the Company; and
- a member who is entitled to cast 2 or more votes may appoint 2 proxies and may specify the proportion or number of votes each proxy is appointed to exercise. If the member appoints 2 proxies and the appointment does not specify the proportion or number of the member's votes, then in accordance with section 249X (3) of the Corporations Act, each proxy may exercise one-half of the votes.

Proxy vote if appointment specifies way to vote

Section 250BB (1) of the Corporations Act provides that an appointment of a proxy may specify the way the proxy is to vote on a particular resolution and, if it does:

- the proxy need not vote on a show of hands, but if the proxy does so, the proxy must vote that way (i.e., as directed); and
- if the proxy has 2 or more appointments that specify different ways to vote on the resolution – the proxy must not vote on a show of hands; and

- if the proxy is the chair of the meeting at which the resolution is voted on – the proxy must vote on a poll, and must vote that way (i.e., as directed); and

- if the proxy is not the chair – the proxy need not vote on the poll, but if the proxy does so, the proxy must vote that way (i.e., as directed).

Transfer of non-chair proxy to chair in certain circumstances

Section 250BC of the Corporations Act provides that, if:

- an appointment of a proxy specifies the way the proxy is to vote on a particular resolution at a meeting of the Company's members; and

- the appointed proxy is not the chair of the meeting; and

- at the meeting, a poll is duly demanded on the resolution; and

- either of the following applies:

    - the proxy is not recorded as attending the meeting;

    - the proxy does not vote on the resolution,

  the chair of the meeting is taken, before voting on the resolution closes, to have been appointed as the proxy for the purposes of voting on the resolution at the meeting.

Dear Shareholder

I am pleased to invite you to the OncoSil Medical Limited EGM which will be held as a virtual meeting https://meetings.lumiconnect.com/300-972-839-431 on Thursday, 12 March 2026, commencing at 10.00am (AEDT).

Enclosed with the Notice of EGM is your personalised proxy form. The following pages contain details of the items of business that you will be able to vote on at the EGM.

On 3 February 2026, the Company announced that:

- **Placement:** the Company had received firm commitments from sophisticated and professional investors to raise approximately $6 million through the issue of new Shares at an issue price of $0.68 per Share (**Placement Shares**), together with, subject to Shareholder approval, one (1) free-attaching listed option exercisable at $0.90 per option and expiring on 30 June 2027 for every Placement Share subscribed for and issued (**Placement Options**), in respect of two tranches as follows;
    - a placement of approximately 4.7 million Placement Shares issued under the Company's existing placement capacity under ASX Listing Rule 7.1 and 7.1A to raise approximately $3.2 million (**Tranche 1**); and
    - a placement of approximately 4.1 million Placement Shares, subject to shareholder approval under ASX Listing Rule 7.1 (and ASX Listing Rule 10.11 for Director participation) to raise approximately $2.8 million (**Tranche 2**); and
- **Entitlement Offer:** the Company is undertaking a non-renounceable entitlement offer to eligible shareholders at $0.68, being the same issue price as under the Placement, to raise up to approximately $2 million by the issue of up to approximately 2.95 million new Shares together with 1 new Option, on the same terms as the Placement Options, for every new Share subscribed under the Entitlement Offer.

The funds raised from the Placement and the Entitlement Offer will be applied to the Company's ongoing clinical investment, investment in its manufacturing facility, sales and marketing investments, market access investment, other general working capital costs and costs of the offers.

Bell Potter Securities Limited ACN 006 390 772, AFSL 243480 (**Lead Manager**) is acting as lead manager to the Placement and underwriter to the Entitlement Offer. The Company will pay the Lead Manager a cash fee equal to 6.0% of the proceeds of the Placement and Entitlement Offer and, subject to shareholder approval, issue such number of Options that equates to 1% of the issued share capital of the Company after the completion of the Placement and the Entitlement Offer, on the same terms as the Placement Options (**Lead Manager Options**).

The resolutions contained in this Notice deal with the proposed shareholder approval of –

- the issue of Tranche 1 Options, Tranche 2 Placement Shares and Tranche 2 Placement Options to investors under the Placement;
- the issue of the Lead Manager Options to the Lead Manager;
- the issue of Tranche 2 Placement Shares to the Directors participating in the Placement – being Nigel Lange, Thomas Duthy and Lel Smits;
- ratification of the prior issue of Tranche 1 Placement Shares to investors under the Placement; and

- the issue of Remuneration Shares to Nigel Lange, in lieu of part of his cash salary under his employment contract.

If you are unable to attend in person, please ensure that you fill and return your personalised proxy form which has been delivered by mail or electronically.

Yours sincerely,

Dr Thomas Duthy
Chairman
12 February 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING

Notice is given that the EGM of shareholders of the Company will be held as a virtual meeting at https://meetings.lumiconnect.com/300-972-839-431 on Thursday, 12 March 2026, commencing at 10.00am (AEDT).

The Explanatory Memorandum to this Notice of EGM provides information on matters to be considered at the EGM. The Explanatory Memorandum and the proxy form are part of this Notice of EGM.

The Directors have determined pursuant to Regulation 7.11.37 of the *Corporations Regulations 2001 (Cth)* that the persons eligible to vote at the EGM are those who are registered shareholders of the Company at 7.00pm (AEDT) on Tuesday, 10 March 2026. Terms and abbreviations used in this Notice of Meeting and Explanatory Memorandum are defined in the Glossary.

AGENDA - GENERAL BUSINESS

RESOLUTION 1(A): APPROVAL OF ISSUE OF TRANCHE 2 PLACEMENT SHARES

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:
"That, pursuant to and in accordance with Listing Rule 7.1 and for all other purposes, Shareholders approve on the terms and conditions in the Explanatory Memorandum, in respect of Tranche 2 of the Placement, the issue of up to 3,938,700 Shares."

RESOLUTION 1(B): APPROVAL OF ISSUE OF PLACEMENT OPTIONS (TRANCHES 1 and 2)

To consider and, if thought fit, to pass with or without amendment, as an **ordinary resolution** the following:
"That, pursuant to and in accordance with Listing Rule 7.1 and for all other purposes, Shareholders approve on the terms and conditions in the Explanatory Memorandum –

- *in respect of Tranche 1 of the Placement the issue of up to 4,723,060 Options; and*
- *in respect of Tranche 2 of the Placement the issue of up to 3,938,700 Options."*

RESOLUTION 2: APPROVAL OF ISSUE OF LEAD MANAGER OPTIONS

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:
"That, pursuant to and in accordance with Listing Rule 7.1 and for all other purposes, the Shareholders approve the issue of up to 306,678 new Options to Bell Potter Securities Limited ACN 006 390 772, AFSL 243480 (and/or its nominee(s)) on the terms and conditions in the Explanatory Memorandum."

RESOLUTION 3: APPROVAL OF DIRECTOR PARTICIPATION IN PLACEMENT - NIGEL LANGE

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:
"That, pursuant to and in accordance with Listing Rule 10.11 and for all other purposes, the Shareholders approve, in respect of Tranche 2 of the Placement, the issue of 73,530 Shares and 73,530 Options to Nigel Lange (and/or his nominee(s)) on the terms and conditions in the Explanatory Memorandum."

RESOLUTION 4: APPROVAL OF DIRECTOR PARTICIPATION IN PLACEMENT - THOMAS DUTHY

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:
"That, pursuant to and in accordance with Listing Rule 10.11 and for all other purposes, the Shareholders approve, in respect of Tranche 2 of the Placement, the issue of 44,120 Shares and 44,120 Options to Thomas Duthy (and/or his nominee(s)) on the terms and conditions in the Explanatory Memorandum."

RESOLUTION 5: APPROVAL OF DIRECTOR PARTICIPATION IN PLACEMENT - LEL SMITS

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:
"That, pursuant to and in accordance with Listing Rule 10.11 and for all other purposes, the Shareholders approve, in respect of Tranche 2 of the Placement, the issue of 44,120 Shares and 44,120 Options to Lel Smits (and/or her nominee(s)) on the terms and conditions in the Explanatory Memorandum."

RESOLUTION 6: RATIFICATION OF PRIOR ISSUES OF PLACEMENT SHARES

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:
"That, for the purposes of ASX Listing Rule 7.4 and for all other purposes, shareholders ratify the allotment and prior issuances of an aggregate of 4,723,060 Shares at an issue price of $0.68 per Share to sophisticated and professional investors under Tranche 1 of the Placement on the terms and conditions in the Explanatory Memorandum."

RESOLUTION 7: APPROVAL OF ISSUE OF REMUNERATION SHARES TO NIGEL LANGE IN LIEU OF SALARY

To consider and, if thought fit, to pass the following resolution as an **ordinary resolution**:
"That, pursuant to and in accordance with Listing Rule 10.11 and for all other purposes, Shareholders approve the issue of 29,509 Shares at an issue price of $1.50 to Nigel Lange (and/or his nominee(s)) on the terms and conditions in the Explanatory Memorandum."

VOTING EXCLUSION STATEMENTS

As required by the ASX Listing Rules and / or the Corporations Act, the Company will disregard votes cast in favour of resolutions as follows:

RESOLUTION 1(A): APPROVAL OF ISSUE OF TRANCHE 2 PLACEMENT SHARES **RESOLUTION 1(B): APPROVAL OF ISSUE OF PLACEMENT**	The Company will disregard any votes cast in favour of this Resolution by or on behalf of a person who is expected to participate in, or who will obtain a material benefit as a result of, the issue of securities (except a benefit solely by reason of being a holder of ordinary securities) or an associate of that person (or those persons). However, this does not apply to a vote cast in favour of this Resolution by: (a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

OPTIONS (TRANCHES 1 and 2)	(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
RESOLUTION 2: ISSUE OF LEAD MANAGER OPTIONS	The Company will disregard any votes cast in favour of this Resolution by or on behalf of Bell Potter Securities Limited (and/or their nominee(s)) or a person who will obtain a material benefit as a result of, the proposed issue (except a benefit solely by reason of being a holder of ordinary securities in the entity) or an associate of that person (or those persons). However, this does not apply to a vote cast in favour of this Resolution by: (d) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or (e) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or (f) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (iii) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and (iv) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
RESOLUTION 3: APPROVAL OF ISSUE OF PLACEMENT SHARES TO NIGEL LANGE **AND** **RESOLUTION 7: APPROVAL OF ISSUE OF REMUNERATION SHARES TO NIGEL LANGE IN LIEU OF SALARY**	The Company will disregard any votes cast in favour of this Resolution by or on behalf of Nigel Lange (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except as benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons). However, this does not apply to a vote cast in favour of this Resolution by: (a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or (b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (v) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and (vi) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
RESOLUTION 4: APPROVAL OF ISSUE OF PLACEMENT SHARES TO THOMAS DUTHY	The Company will disregard any votes cast in favour of this Resolution by or on behalf of Thomas Duthy (and/or his nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except as benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons). However, this does not apply to a vote cast in favour of this Resolution by: (a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or

	(b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
RESOLUTION 5: APPROVAL OF ISSUE OF PLACEMENT SHARES TO LEL SMITS	The Company will disregard any votes cast in favour of this Resolution by or on behalf of Lel Smits (and/or her nominee(s)) and any other person who will obtain a material benefit as a result of the issue of the securities (except as benefit solely by reason of being a holder of ordinary securities in the Company) or an associate of that person (or those persons). However, this does not apply to a vote cast in favour of this Resolution by: (a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or (b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.
RESOLUTION 6: RATIFICATION OF PRIOR ISSUES UNDER THE PLACEMENT	The Company will disregard any votes cast in favour of this Resolution by or on behalf of a person who participated in the issue or an associate of that person (or those persons). However, this does not apply to a vote cast in favour of this Resolution by: (a) a person as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with directions given to the proxy or attorney to vote on this Resolution in that way; or (b) the Chairperson as proxy or attorney for a person who is entitled to vote on this Resolution, in accordance with a direction given to the Chairperson to vote on this Resolution as the Chairperson decides; or (c) a holder acting solely in a nominee, trustee, custodial or other fiduciary capacity on behalf of a beneficiary provided the following conditions are met: (i) the beneficiary provides written confirmation to the holder that the beneficiary is not excluded from voting, and is not an associate of a person excluded from voting, on this Resolution; and (ii) the holder votes on this Resolution in accordance with directions given by the beneficiary to the holder to vote in that way.

Dated 12 February 2026

BY ORDER OF THE BOARD - Tim Luscombe, Company Secretary

EXPLANATORY MEMORANDUM

This Explanatory Memorandum has been prepared for the information of the Shareholders of the Company in connection with the business to be conducted as the EGM of the Company, to be held as a virtual meeting at https://meetings.lumiconnect.com/300-972-839-431 on **Thursday, 12 March 2026,** commencing at **10.00am** (Melbourne time).

The purpose of this Explanatory Memorandum is to provide information that the directors believe to be material to Shareholders in deciding whether or not to pass the Resolution in the Notice of EGM.

BACKGROUND TO THE PLACEMENT

Placement

On 3 February 2026, the Company announced that it had received firm commitments (**Placement**) from sophisticated and professional investors to raise approximately $6 million (before costs) through the issue of up to approximately 8.8 million new Shares at an issue price of $0.68 per Share (**Placement Shares**) and together with, subject to shareholder approval, one (1) free-attaching listed option, expiring on 30 June 2027 for every Placement Share subscribed for and issued (**Placement Options**).

The Placement is being conducted in two tranches:

(a) a placement of up to 4,723,060 Shares (**Tranche 1 Placement Shares**) utilising the Company's existing placement capacity under Listing Rule 7.1 and 7.1A (see Resolution 6 for ratification) and subject to Shareholder approval under ASX Listing Rule 7.1, 4,723,060 Options (**Tranche 1 Placement Options**); and

(b) a placement, subject to shareholder approval under ASX Listing Rule 7.1 (or ASX Listing Rule 10.11 for Director participation), of up to 4,100,470 Shares (**Tranche 2 Placement Shares**) and 4,100,470 Options (**Tranche 2 Placement Options**).

161,770 of the Tranche 2 Placement Shares and 161,770 of the Tranche 2 Placement Options included in (a) above relate to Director participation in the Placement (see Resolutions 3 to 5).

In addition, on 3 February 2026, the Company announced that it is conducting a non-renounceable entitlement offer to eligible shareholders to raise up to approximately $2 million (**Entitlement Offer**).

Please refer to the Company's ASX announcements on, and after, 3 February 2026 (including the Prospectus lodged with ASX on 3 February 2026) for further details in relation to the Placement and Entitlement Offer.

Lead Manager

Bell Potter Securities Limited ACN 006 390 772, AFSL 243480 (**Lead Manager**) is acting as lead manager to the Placement and underwriter to the Entitlement Offer. The Company will pay the Lead Manager a cash fee equal to 6.0% of the total amount raised under the Placement and issue, subject to Shareholder approval, Options equal to 1.0% of the total number of fully paid ordinary shares in the Company following completion of the Placement and Entitlement Offer to the Lead Manager (and/or its nominees) for a nominal issue price as consideration for the services provided by the Lead Manager (**Lead Manager Options**).

The Lead Manager Options are on the same terms as the Placement Options (i.e. exercisable at $0.90 per option and expiring on 30 June 2027). The Lead Manager Options are subject to Shareholder approval under ASX Listing Rule 7.1 (see Resolution 2).

Indicative use of funds

The funds raised from the Placement and the Entitlement Offer will be applied to the Company's ongoing clinical investment, investment in its manufacturing facility, sales and marketing investments, market access investment, other general working capital costs and costs of the offers.

The proposed uses of funds are indicative only and will be subject to modification on an ongoing basis depending on the results obtained from the Company's activities and other factors relevant to the Board's discretion as to usage of funding.

RESOLUTIONS 1(A) AND 1(B): APPROVAL OF ISSUE OF PLACEMENT SHARES (TRANCHE 2) AND PLACEMENT OPTIONS (TRANCHES 1 and 2)

Background

Resolution 1(A) seeks Shareholder approval pursuant to and in accordance with Listing Rule 7.1 for the issue of up to 3,938,700 Placement Shares (being the Tranche 2 Placement Shares, excluding Director participation).

Resolution 1(B) seeks Shareholder approval pursuant to and in accordance with Listing Rule 7.1 for the issue of up to:

- 4,723,060 Placement Options (being the Tranche 1 Placement Options); and
- 3,938,700 Placement Options (being the Tranche 2 Placement Options, excluding Director participation).

Each of the Shares issued under the Placement are proposed to be accompanied by attaching options on the basis of one (1) Placement Option for every one (1) Placement Share. The terms and conditions of the Placement Options are detailed in Annexure A.

Director participation under Tranche 2 of the Placement is subject to separate Shareholder approvals under ASX Listing Rule 10.11 (see Resolutions 3 to 5).

Resolutions 1(A) and 1(B) are ordinary resolutions.

The Chairperson intends to exercise all available undirected proxies in favour of Resolutions 1(A) and 1(B).

Listing Rule 7.1

Under Listing Rule 7.1, a company may issue up to 15% of its ordinary share capital in any 12- month rolling period without Shareholder approval (**15% Placement Capacity**).

The issue of the Tranche 2 Placement Shares, Tranche 1 Placement Options and Tranche 2 Placement Options do not fall within any of the exceptions to Listing Rule 7.1 and, as the Company does not have sufficient existing capacity under its 15% Placement Capacity to issue those securities, Shareholder approval under Listing Rule 7.1 is being sought for the issue of the Tranche 2 Placement Shares, Tranche 1 Placement Options and Tranche 2 Placement Options.

Resolution 1(A) seeks the required Shareholder approval to issue up to 3,938,700 Shares (being the Tranche 2 Placement Shares, excluding Director participation), for the purposes of Listing Rule 7.1 (and for all other purposes). Resolution 1(B) seeks the required Shareholder approval to issue up to 4,723,060 Options (being the Tranche 1 Placement Options) and up to 3,938,700 Options (being the Tranche 2 Placement Options, excluding Director participation) for the purposes of Listing Rule 7.1 (and for all other purposes).

If Resolutions 1(A) and 1(B) are passed, the Company will be able to proceed with the issue of the Tranche 2 Placement Shares, Tranche 1 Placement Options and Tranche 2 Placement Options. In addition, the issue of the Tranche 2 Placement Shares, Tranche 1 Placement Options and Tranche 2 Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolutions 1(A) and 1(B) are not passed, the issue of the Tranche 2 Placement Shares, Tranche 1 Placement Options and Tranche 2 Placement Options will not proceed and the Company will not be able to raise funds from issuing the Tranche 2 Placement Shares.

If Resolution 1(A) is passed but Resolution 1(B) is not passed, the issue of the Tranche 2 Placement Shares will proceed but the issue of the Tranche 1 Placement Options and Tranche 2 Placement Options will not proceed. In addition, the issue of the Tranche 2 Placement Shares will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 1(A) is not passed but Resolution 1(B) is passed, the issue of the Tranche 2 Placement Shares and Tranche 2 Placement Options will not proceed and the Company will not be able to raise funds from issuing the Tranche 2 Placement Shares. However, the issue of the Tranche 1 Placement Options will proceed (as the Tranche 1 Placement Options are attaching options to the Tranche 1 Placement Shares which have already been issued). In addition, the issue of the Tranche 1 Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

Specific information required by Listing Rule 7.3

The following information in relation to Resolutions 1(A) and 1(B) is provided to Shareholders for the purposes of Listing Rule 7.3:

(a) The Tranche 2 Placement Shares, Tranche 1 Placement Options and the Tranche 2 Placement Options will be issued to professional and sophisticated investors identified by the Lead Manager, none of whom are a Material Investor except as follows:

As disclosed in the Company's Prospectus as lodged with ASX on 3 February 2026, Pengana Capital Limited in respect of the Pengana High Conviction Equities Fund (**Pengana**) which is currently the Company's largest substantial shareholder (holding approximately 18.12% of the Company's issued Shares on an undiluted basis as at the date of the Prospectus), is participating in the capital raising by:

- accepting its entitlement under the Entitlement Offer in full;
- committing additional funds under the Placement (which would take it to a 19.99% relevant interest in the Company); and
- sub-underwriting up to approximately 52% of any shortfall under the Entitlement Offer (however Pengana has no priority or firm entitlement under its sub-underwriting commitment to any specified amount under a shortfall.).

Pengana's maximum proportion of the issued Shares of the Company on completion of the Placement and Entitlement Offer is 23.14% (on an undiluted basis).

(b) The maximum number of securities the Company may issue is:

- 3,938,700 Placement Shares (being the Tranche 2 Placement Shares, excluding Director participation);
- 4,723,060 Placement Options (being the Tranche 1 Placement Options); and
- 3,938,700 Placement Options (being the Tranche 2 Placement Options, excluding Director participation).

(c) Each of the Tranche 1 Placement Options and Tranche 2 Placement Options have an exercise price of $0.90 each and will expire on 30 June 2027. The terms and conditions of the Options are detailed in Annexure A. The Tranche 2 Placement Shares are fully paid ordinary shares in the capital of the Company.

(d) Where Resolutions 1(A) and 1(B) are approved, the Tranche 2 Placement Shares, Tranche 1 Placement Options and Tranche 2 Placement Options are expected to be issued on or around 17 March 2026 and in any case, by no later than three months following the date of the Meeting.

(e) The issue price for the Tranche 2 Placement Shares is $0.68 per Share, amounting to a total of approximately $2,678,316 to be received by the Company for the subscription of Tranche 2 Placement Shares by Placement investors. The Tranche 1 Placement Options

and Tranche 2 Placement Options will be issued for nil cash consideration, as they are free-attaching on the basis of one (1) Option for every one (1) Share issued under the Placement.

(f) The funds raised from issue of the Tranche 2 Placement Shares, together with remaining funds raised under the Placement and Entitlement Offer, will be applied to the Company's ongoing clinical investment, investment in its manufacturing facility, sales and marketing investments, market access investment, other general working capital costs and costs of the offers.

(g) A voting exclusion is included in the Notice for Resolutions 1(A) and 1(B).

Board recommendations

The Directors of the Company unanimously recommend shareholders vote in favour of Resolutions 1(A) and 1(B).

RESOLUTION 2: APPROVAL OF ISSUE OF LEAD MANAGER OPTIONS

Background

As noted previously, Bell Potter Securities Limited (ACN 006 390 772, AFSL 243480) is acting as the Lead Manager to the Placement and underwriter of the Entitlement Offer. Subject to Shareholder approval under ASX Listing Rule 7.1, the Company agreed to issue the Lead Manager Options to the Lead Manager (and/or its nominee(s)), as part-consideration for the services provided by the Lead Manager.

Resolution 2 seeks Shareholder approval pursuant to and in accordance with Listing Rule 7.1 for the issue of up to 306,678 Lead Manager Options to the Lead Manager (and/or its nominee(s)).

The terms and conditions of the Lead Manager Options are outlined in Annexure A to this Notice.

Resolutions 2 is an ordinary resolution. The Chairperson intends to exercise all available undirected proxies in favour of Resolution 2.

Listing Rule 7.1

As noted above, broadly speaking and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without shareholder approval over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

The Company does not have sufficient existing placement capacity under its 15% Placement Capacity to issue the Lead Manager Options. The issue of the Lead Manager Options is conditional on Shareholder approval.

If Resolution 2 is passed, the Company will be able to proceed with the issue of the Lead Manager Options and the Lead Manager Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 2 is not passed, the issue of the Lead Manager Options will not proceed. In the event that Shareholders do not approve the issue of the Lead Manager Options, in accordance with the terms of the Underwriting Agreement between the Company and the Lead Manager dated 3 February 2026, the Company must reimburse the Lead Manager the value of the Lead Manager Options in cash (using a Black Scholes valuation having an indicative value of $160,085) in lieu of the issue of securities.

Specific information required by Listing Rule 7.3

The following information in relation to Resolutions 2 is provided to Shareholders for the purposes of Listing Rule 7.3:

(a) The Lead Manager Options will be issued to Bell Potter Securities Limited (ACN 006 390 772,

AFSL 243480) (and/or its nominee(s)).

(b) The maximum number of Lead Manager Options the Company may issue to the Lead Manager (and/or its nominee(s)) is 306,678 Lead Manager Options.

(c) The Lead Manager Options will have an exercise price of $0.90 each and will expire on 30 June 2027. The terms and conditions of the Options are detailed in Annexure A.

(d) Where Resolution 2 is approved, the Lead Manager Options are expected to be issued on or around 17 March 2026 and in any case, by no later than three months following the date of the Meeting.

(e) The Lead Manager Options will be issued for nominal consideration of $0.00001 per Option.

(f) The Lead Manager Options are proposed to be issued as part-consideration for the Lead Manager's services to the Company of acting as Lead Manager the Placement and underwriter to the Entitlement Offer.

(g) The Lead Manager Options are being issued pursuant to an Underwriting Agreement between the Company and the Lead Manager dated 3 February 2026. The Underwriting Agreement provides that, in consideration for the Lead Manager providing lead manager and underwriting services to the Company in relation to the Placement and Entitlement Offer, the Company will:

  (i) pay a cash fee to the Lead Manager of 6.0% of the total proceeds of the Placement and Entitlement Offer; and

  (ii) subject to Shareholder approval, issue to the Lead Manager (and/or its nominee(s)) the Lead Manager Options, being equivalent to 1.0% of the total number of fully paid ordinary shares in the Company following completion of the Placement and Entitlement Offer.

(h) A voting exclusion is included in the Notice for Resolution 2.

Board Recommendation

The Directors of the Company unanimously recommend Shareholders vote in favour of Resolution 2.

RESOLUTIONS 3, 4 AND 5: DIRECTOR PARTICIPATION IN THE PLACEMENT – NIGEL LANGE, THOMAS DUTHY AND LEL SMITS

Background

Resolutions 3, 4 and 5 seek Shareholder approval pursuant to and in accordance with Listing Rule 10.11 (and for all other purposes) to issue (in aggregate) 161,770 Placement Shares and the attaching 161,770 Placement Options (with an exercise price of $0.90 and an expiry date of 30 June 2027) to Nigel Lange, Thomas Duthy and Lel Smits, being Directors of the Company, pursuant to the Placement and on the same terms as unrelated participants.

Any participation by the Directors under the Placement is excluded from the total number of Tranche 1 Placement Options, Tranche 2 Placement Shares and Tranche 2 Placement Options for which Shareholder approval is sought under Resolutions 1(A) and 1(B).

In accordance with Listing Rule 10.11, Shareholder approval is required for the issue of Equity Securities to a related party. Nigel Lange, Thomas Duthy and Lel Smits are each a related party of the Company by virtue of being a Director.

Resolutions 3, 4 and 5 are ordinary resolutions.

The Chairperson intends to exercise all available undirected proxies in favour of Resolutions 3, 4 and 5.

Chapter 2E of the Corporations Act

Pursuant to the Corporations Act, the provision of any financial benefit to a related party requires shareholder approval in accordance with the procedure set out in Part 2E.1 of that Act, unless a relevant exception applies. Part 2E.1 applies to the issuance of securities to a related party by the Company to a related party. A "related party" (as defined in the Act) includes the Directors of the Company and their controlled entities.

With respect to Resolutions 3, 4 and 5, the Board is of the view that the Placement Shares and Placement Options proposed to be issued to the Directors would be issued upon terms that would meet the "arm's length terms" criteria of Section 210 of the Corporations Act (and would therefore be exempt from the need to seek shareholder approval pursuant to the Act).

In particular, the subscription price for the Placement Shares payable by the Directors:

- was determined at the same time as, and are the same as, the Placement Shares issued to the non-related party, independent sophisticated and professional investors pursuant to the Placement; and
- is the same as the subscription price under the Entitlement Offer paid by eligible shareholders who subscribed under the Entitlement Offer.

Listing Rule 10.11

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue Equity Securities to:

(a) a related party;

(b) a person who is, or was at any time in the six months before the issue or agreement, a substantial (30%+) holder in the company;

(c) a person who is, or was at any time in the six months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;

(d) an associate of a person referred to in (a) to (c); or

(e) a person whose relationship with the company or a person referred to in (a) to (d) is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains shareholder approval.

The issue of Placement Shares and Placement Options under Resolutions 3, 4 and 5 fall within paragraph (a) above (being Listing Rule 10.11.1), as each of Nigel Lange, Thomas Duthy and Lel Smits are a related party of the Company by virtue of being a Director, and the issues do not fall within any of the exceptions in Listing Rule 10.12.

If Resolutions 3, 4 and 5 are passed, the Company will be able to proceed with the issue of the relevant Placement Shares and Placement Options to Nigel Lange, Thomas Duthy and Lel Smits (and/or their respective nominee(s)). In addition, the issue of the Placement Shares and Placement Options will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 3, 4 or 5 are not passed, the Company will not be able to proceed with the issue of the Placement Shares and Placement Options to Nigel Lange, Thomas Duthy or Lel Smits (and/or their respective nominee(s)) as applicable. In addition, the Company will not be able to raise funds from issuing Placement Shares to the relevant Director(s).

Specific information required by Listing Rule 10.13

The following information in relation to Resolutions 3, 4 and 5 is provided to Shareholders for the purposes of Listing Rule 10.13:

(a) The Placement Shares and Placement Options will be issued to Nigel Lange, Thomas Duthy and Lel Smits (and/or their nominee(s)).

(b) Nigel Lange, Thomas Duthy and Lel Smits each fall within Listing Rule 10.11.1 as each of them is a Director and therefore a related party of the Company.

(c) The maximum number of Placement Shares and Placement Options that may be issued to the Directors is:

- Nigel Lange - 73,530 Placement Shares and 73,530 Placement Options
- Thomas Duthy - 44,120 Placement Shares and 44,120 Placement Options
- Lel Smits - 44,120 Placement Shares and 44,120 Placement Options

(d) The Placement Options have an exercise price of $0.90 each and will expire 30 June 2027. The terms and conditions of the Placement Options are detailed in Annexure A. The Placement Shares are fully paid ordinary shares in the capital of the Company.

(e) The Placement Shares and Placement Options will be issued on or around 17 March 2026, and in any event by no later than 1 month after the date of this Meeting.

(f) The issue price for the Placement Shares is $0.68 per Share, amounting to a total of approximately $110,000 to be received by the Company for the subscription of Placement Shares by the Directors. The Placement Options will be issued for nil cash consideration, as they are free-attaching on the basis of one (1) Option for every Share issued under the Placement.

(g) The funds raised from issue of the Placement Shares, together with remaining funds raised under the Placement and Entitlement Offer, will be applied to the Company's ongoing clinical investment, investment in its manufacturing facility, sales and marketing investments, market access investment, other general working capital costs and costs of the offers.

(h) A voting exclusion statement is included in the Notice for Resolutions 3, 4 and 5.

Board recommendations

The Directors of the Company (with Nigel Lange abstaining) recommend Shareholders vote in favour of Resolution 3.

The Directors of the Company (with Thomas Duthy abstaining) recommend Shareholders vote in favour of Resolution 4.

The Directors of the Company (with Lel Smits abstaining) recommend Shareholders vote in favour of Resolution 5.

RESOLUTION 6: RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES

Background

As described in the Background of this Explanatory Memorandum, on 3 February 2026, the Company announced the Placement consisting of firm commitments from sophisticated and professional investors to raise approximately $6 million (before costs) through the issue of up to approximately 8.8 million Placement Shares, with one (1) Placement Option for each Placement Share subscribed for and issued under the Placement.

The Tranche 1 Placement Shares of 4,723,060 Shares were issued to the Placement investors on 9 February 2026 pursuant to the Company's existing ASX Listing Rules 7.1 and 7.1A capacity. By issuing those Tranche 1 Placement Shares the Company's capacity to issue further equity securities without Shareholder approval within the limits of ASX Listing Rule 7.1 and 7.1A was correspondingly reduced. Accordingly, Shareholder approval is being sought to ratify the prior issue and allotment of the Tranche 1 Placement Shares to Placement investors.

For clarity, approval under this Resolution 6 is to ratify a prior issue which has occurred prior to the date of the Meeting.

Listing Rules 7.1, 7.1A and 7.4

ASX Listing Rule 7.1 provides that a company must not, subject to certain exceptions, issue or agree to issue more equity securities in any rolling 12 month period other than the amount which is equal to 15% of its fully paid ordinary securities on issue at the start of that 12 month period (**15% capacity**).

ASX Listing Rule 7.1A provides that, in addition to issues under the 15% capacity, a company which has obtained the approval of its shareholders under ASX Listing Rule 7.1A in respect of a relevant period, may issue or agree to issue equity securities of an additional amount which is equal to 10% of its fully paid ordinary securities on issue at the start of that 12 month period (**10% additional capacity**).

Listing Rule 7.4 allows the Shareholders of the Company to approve an issue of equity securities after it has been made or agreed to be made. If Shareholders approve the issue, the issue is taken to have been approved under Listing Rule 7.1 and so does not reduce the Company's capacity to issue further equity securities without Shareholder approval under that rule (i.e. by ratifying this previous issue, the Company will retain the flexibility to issue equity securities in the future (equal to the number of securities for which this approval is being sought) within the limits of ASX Listing Rules 7.1 and 7.1A without needing to seek further Shareholder approval).

If Resolution 6 is passed, the Tranche 1 Placement Shares to Placement investors will be **excluded** in calculating the Company's 15% capacity in Listing Rule 7.1 and 10% additional capacity in Listing Rule 7.1A, effectively increasing the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date.

If Resolution 6 is not passed, the issue of the Tranche 1 Placement Shares will be **included** in calculating the Company's 15% capacity in Listing Rule 7.1 and 10% additional capacity under Listing Rule 7.1A, in the number of equity securities it can issue without Shareholder approval over the 12-month period following the issue date. The Company wishes to retain as much flexibility as possible to issue additional equity securities into the future without having to obtain Shareholder approval under Listing Rule 7.1.

Accordingly, Resolution 6 seeks Shareholder approval to allow the Company to refresh its placement capacity under ASX Listing Rule 7.1 and 7.1A with respect to the Tranche 1 Placement Shares issued to Placement investors prior to the date of this Meeting.

Information required by Listing Rule 7.5

The following information in relation to Resolutions 6 is provided to Shareholders for the purposes of Listing Rule 7.5:

(a) The Tranche 1 Placement Shares were issued to sophisticated and professional investors identified by the Lead Manager, Bell Potter Securities Limited, none of whom are a Material Investor except as follows:

As disclosed in the Company's Prospectus as lodged with ASX on 3 February 2026, Pengana which is currently the Company's largest substantial shareholder (holding approximately 18.12% of the Company's issued Shares on an undiluted basis as at the date of the Prospectus), is participating in the capital raising by:

- accepting its entitlement under the Entitlement Offer in full;
- committing additional funds under the Placement (which would take it to a 19.99% relevant interest in the Company); and

- sub-underwriting up to approximately 52% of any shortfall under the Entitlement Offer (however Pengana has no priority or firm entitlement under its sub-underwriting commitment to any specified amount under a shortfall.).

Pengana's maximum proportion of the issued Shares of the Company on completion of the Placement and Entitlement Offer is 23.14% (on an undiluted basis).

(b) The Company issued 4,723,060 Placement Shares (being the Tranche 1 Placement Shares),

(c) The Tranche 1 Placement Shares are fully paid ordinary shares in the capital of the Company.

(d) The Tranche 1 Placement Shares were issued on 9 February 2026.

(e) The issue price for the Tranche 1 Placement Shares was $0.68 per Share, amounting to a total of approximately $3,211,680 received by the Company for the subscription of Tranche 1 Placement Shares by Placement investors.

(f) The funds raised from issue of the Tranche 1 Placement Shares, together with remaining funds raised under the Placement and Entitlement Offer, will be applied to the Company's ongoing clinical investment, investment in its manufacturing facility, sales and marketing investments, market access investment, other general working capital costs and costs of the offers.

(g) A voting exclusion is included in the Notice for Resolution 6.

Board Recommendation

The directors of the Company unanimously recommend shareholders vote in favour of Resolution 6.

RESOLUTION 7: APPROVAL OF ISSUE OF REMUNERATION SHARES TO NIGEL LANGE IN LIEU OF SALARY

Background

Nigel Lange, the Company's Chief Executive Office and Managing Director, has agreed with the Company, subject to Shareholder approval, to have 10% of his base salary under his employment contract paid out Shares (in lieu of cash salary) for the 12-month period commencing on 1 February 2026 (**Remuneration Shares**).

Under the terms of Mr Lange's variation to his employment contract, the Remuneration Shares shall have an issue price of $1.50 per Share and will be subject to escrow for a period of 12 months from the date of issue. At an issue price of $1.50 per Shares, 10% of Mr Lange's base salary equates to 29,509 Shares.

The issue price per Remuneration Share was determined by the Board of Directors considering an appropriate alignment between Mr Lange and fellow Directors Lel Smits and Thomas Duthy who previously elected to receive Shares in lieu of Director's fees at $1.50 per Share, representing a 25% premium to the previous capital raise price of $1.20 undertaken in May 2025.

Mr Lange has agreed to the variation to his employment contract to accept an issue of Shares in lieu of part of his cash salary as a show of confidence in the Company, to continue to align his interests with the interests of Shareholders, and to assist in preserving the cash resources of the Company.

Resolution 7 seek Shareholder approval pursuant to and in accordance with Listing Rule 10.11 (and for all other purposes) to issue 29,509 Shares to Nigel Lange (and/or his nominee),

In accordance with Listing Rule 10.11, Shareholder approval is required for the issue of Equity Securities to a related party. Nigel Lange is a related party of the Company by virtue of being a Director.

Resolution 7 is an ordinary resolution.

The Chairperson intends to exercise all available undirected proxies in favour of Resolution 7.

Chapter 2E of the Corporations Act

Pursuant to the Corporations Act, the provision of any financial benefit to a related party requires shareholder approval in accordance with the procedure set out in Part 2E.1 of that Act, unless a relevant exception applies. Part 2E.1 applies to the issuance of securities to a related party by the Company to a related party. A "related party" (as defined in the Act) includes the Directors of the Company and their controlled entities.

With respect to Resolution 7, the Board (with Nigel Lange abstaining) is of the view that the Remuneration Shares proposed to be issued to Nigel Lange would be issued upon terms that would meet the "reasonable remuneration" criteria of Section 211 of the Corporations Act (and would therefore be exempt from the need to seek shareholder approval pursuant to Chapter 2E of the Act).

In reaching this view, the Directors have given consideration to:

- the issue price for the Remuneration Shares was determined by the Board considering an appropriate alignment between Mr Lange and fellow Directors Lel Smits and Thomas Duthy, who previously elected to receive issues of Shares in lieu of Director's fees;
- the issue price for the Remuneration Shares exceeds the recent market price of Shares, for example, the issue price of $1.50 per Share is at a 26% premium to the 90-day VWAP of Shares as at 29 January 2026 of $1.1953; and
- the Remuneration Shares are being issued in lieu of cash salary equal to 10% of Mr Lange's base salary (which the Company will not be required to pay in cash for the 12-month period commencing on 1 February 2026).

Listing Rule 10.11

Listing Rule 10.11 provides that unless one of the exceptions in Listing Rule 10.12 applies, a listed company must not issue or agree to issue Equity Securities to:

(f) a related party;

(g) a person who is, or was at any time in the six months before the issue or agreement, a substantial (30%+) holder in the company;

(h) a person who is, or was at any time in the six months before the issue or agreement, a substantial (10%+) holder in the company and who has nominated a director to the board of the company pursuant to a relevant agreement which gives them a right or expectation to do so;

(i) an associate of a person referred to in (a) to (c); or

(j) a person whose relationship with the company or a person referred to in (a) to (d) is such that, in ASX's opinion, the issue or agreement should be approved by its shareholders,

unless it obtains shareholder approval.

The issue of Remuneration Shares under Resolution 7 falls within paragraph (a) above (being Listing Rule 10.11.1), as Nigel Lange is a related party of the Company by virtue of being a Director, and the issues not fall within any of the exceptions in Listing Rule 10.12.

If Resolution 7 is passed, the Company will be able to proceed with the issue of the Remuneration Shares to Nigel Lange (and/or his nominee(s)) and the Company will not be required to pay cash salary equal to 10% of Mr Lange's base salary for the 12-month period commencing on 1 February 2026 (being an amount of approximately $44,263). In addition, the issue of the Remuneration Shares will be excluded from the calculation of the number of Equity Securities that the Company can issue without Shareholder approval under Listing Rule 7.1.

If Resolution 7 is not passed, the Company will not be able to proceed with the issue of the Remuneration Shares to Nigel Lange (and/or his nominee(s)). In addition, the Company will be required to pay cash salary equal to 10% of Mr Lange's base salary for the 12-month period commencing on 1 February 2026 (being an amount of approximately $44,263) and will not benefit from Mr Lange's agreement to be issued Shares in lieu of part of his cash salary.

Specific information required by Listing Rule 10.13

The following information in relation to Resolution 7 is provided to Shareholders for the purposes of Listing Rule 10.13:

(a) The Remuneration Shares will be issued to Nigel Lange (and/or his nominee(s)).

(b) Nigel Lange falls within Listing Rule 10.11.1 as he is a Director and therefore a related party of the Company.

(c) The maximum number of Remuneration Shares that may be issued is 29,509 Shares.

(d) The Remuneration Shares are fully paid ordinary shares in the capital of the Company.

(e) The Remuneration Shares will be issued by no later than 1 month after the date of this Meeting.

(f) The issue price for the Remuneration Shares is $1.50 per Share amounting to a total value of approximately $44,263.

(g) The issue of Remuneration Shares is proposed to form part of Nigel Lange's remuneration package. No funds will be received by the Company for the issue of the Remuneration Shares, which are proposed to be issued in lieu of payment of cash salary equal to 10% of Nigel Lange's base salary under his employment contract.

(h) Nigel Lange's current remuneration package is base salary of €260,000 per annum. Additional benefits of motor vehicle, medical insurance and statutory pension entitlements (value approximately €25,000 per annum). Cash bonus of up to 35% of base salary subject to achievement of KPI's as agreed with the Board. Mr Lange is eligible to participate in the long-term incentive plan up to 35% of base salary.

(i) The Remuneration Shares are being issued under a variation to Nigel Lange's employment contract, the material terms of which are included in the 'Background' section above.

(j) A voting exclusion statement is included in the Notice for Resolution 7.

Board recommendations

The Directors of the Company (with Nigel Lange abstaining) recommend Shareholders vote in favour of Resolution 7.

FURTHER INFORMATION

The Directors are not aware of any other information which is relevant to the consideration by members of the proposed resolution set out in the notice of extraordinary general meeting.

The Directors recommend members read these explanatory notes in full and, if desired, seek advice from their own independent financial or legal adviser as to the effect of the proposed resolution before making any decision in relation to the proposed resolution.

GLOSSARY OF KEY TERMS

In addition to terms defined within the Notice and Explanatory Memorandum in bold, the following defined terms apply:

Extraordinary General Meeting or **Meeting** means the meeting convened by this Notice.

ASX means ASX Limited.

ASX Listing Rules or **Listing Rules** means the Listing Rules of ASX.

Board means the Board of Directors.

Chair means the chair of the Meeting.

Company or **OncoSil Medical** means OncoSil Medical Ltd ACN 113 824 141.

Constitution means the constitution of the Company.

Corporations Act means the Corporations Act 2001 (Cth).

Director means a director of the Company.

Explanatory Memorandum means the explanatory memorandum accompanying the Notice.

Equity Securities means securities in the Company including Shares and Options.

Lead Manager means Bell Potter Securities Limited ACN 006 390 772, AFSL 243480.

Material Investor means in relation to the Company:

(a) a related party;

(b) key management personnel;

(c) a substantial Shareholder;

(d) an advisor; or

(e) an associate of the above,

who is being issued more than 1% of the Company's issued capital as at the time of issue.

Notice or **Notice of Meeting** means this notice of meeting including the Explanatory Memorandum and the Proxy Form.

Option means an option to acquire a Share, with the terms and conditions as specified in Annexure A to this Notice of Meeting.

Proxy Form means the proxy form accompanying the Notice.

Resolution means the resolution set out in the Notice.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a holder of a Share.

VWAP has the meaning given to the term 'volume weighted average market price' in the ASX Listing Rules.

Annexure A - Terms and conditions of Tranche 1 Placement Options, Tranche 2 Placement Options and Lead Manager Options

Each option (**Option**) entitles the holder (**Option Holder**) to subscribe for and be issued one fully paid ordinary share (**Share**) in **OncoSil Medical Limited** ACN 113 824 141 (**Company**) on the following terms:

1. Subject to clause 2 and any restrictions imposed by the ASX Limited (**ASX**), each Option is exercisable at any time after the date it is issued (**Issue Date**), until and including their expiry date, namely 5.00 pm (AEDT) on 30 June 2027 (**Expiry Date**). Any Options not exercised by the Expiry Date will automatically lapse at 5pm on the Expiry Date.
2. The Options may be exercised for part or all of the Options held at a particular time by the Option Holder paying to the Company at its registered office prior to the Expiry Date the exercise price of A$0.90 per Option (**Exercise Price**).
3. The Company will apply for quotation of the Options. Quotation of the Options is subject to compliance with the ASX Listing Rules (including ASX Listing Rule 2.5).
4. On receipt by the Company of the payment of the Exercise Price, the Company must, within 4 Business Days and if the Shares are listed on the ASX within the time period prescribed by the Listing Rules of the ASX (ASX Listing Rules):
   (a) allot to the Option Holder one Share in the Company for each Option exercised by the Option Holder;
   (b) cause to be dispatched to the Option Holder the relevant acknowledgement of issue, a holding statement or share certificate (as applicable) as soon as is reasonably practicable detailing the issue of the relevant Share/s; and
   (c) issue (if applicable) a new holding statement (or option certificate) for the balance of the Options that remain unexercised.
5. Shares allotted on the exercise of Options will rank equally in all respects with the then existing issued ordinary fully paid shares in the capital of the Company (except in respect to any dividends which shall have been declared but not yet distributed before the actual exercise of an Option) and will be subject to the provisions of the Constitution of the Company.
6. The Options are transferable in accordance with the ASX Listing Rules.
7. If any reorganisation (including consolidation, subdivision, reduction, return or cancellation) of the issued capital of the Company occurs before the expiry of any Options, the number of Options to which each Option Holder is entitled or the Exercise Price of his or her Options or both must be reorganised in accordance with the ASX Listing Rules applying to a reorganisation at the time of the reorganisation (which adjustment formula will apply even where the Company is not admitted to the ASX Official List).
8. An Option does not confer the right to participate in new issues of capital offered to holders of Shares during the currency of the Options without exercising the Options. However, the Company will use reasonable endeavours to see that for the purpose of determining Rights Entitlements to any such issue, the Option Holder is to receive at least 2 Business Days written notice from the Company of the pending closing or record date and sufficient time for the Option Holder to exercise the Options prior to that closing or record date in order to qualify for participation.
9. In the event of the liquidation of the Company, all unexercised Options will lapse upon the occurrence of that liquidation.
10. The Options do not provide any entitlement to dividends paid to ordinary shareholders.
11. The Options do not entitle the Option Holder to vote at any meeting of shareholders
12. To the extent (if any) that any of these Option Terms and Conditions are inconsistent with or contrary to the ASX Listing Rules, the ASX Listing Rules provisions will prevail and these Option Terms and Conditions are deemed to incorporate the relevant ASX Listing Rules provisions as an amendment to these terms; and
13. These Option Terms and Conditions are governed by the laws of Victoria. The parties submit to the non-exclusive jurisdiction of the courts of Victoria.

All Correspondence to:

By Mail Boardroom Pty Limited
GPO Box 3993
Sydney NSW 2001 Australia

By Fax: +61 2 9290 9655

Online: www.boardroomlimited.com.au

By Phone: (within Australia) 1300 737 760
(outside Australia) +61 2 9290 9600

YOUR VOTE IS IMPORTANT

For your vote to be effective it must be recorded **10.00am (AEDT) on Tuesday, 10 March 2026.**

TO APPOINT A PROXY ONLINE

BY SMARTPHONE

STEP 1: VISIT https://www.votingonline.com.au/oslegm26

STEP 2: Enter your Postcode OR Country of Residence (if outside Australia)

STEP 3: Enter your Voting Access Code (VAC):

Scan QR Code using smartphone
QR Reader App

TO VOTE BY COMPLETING THE PROXY FORM

STEP 1 APPOINTMENT OF PROXY

Indicate who you want to appoint as your Proxy.

If you wish to appoint the Chair of the Meeting as your proxy, mark the box. If you wish to appoint someone other than the Chair of the Meeting as your proxy please write the full name of that individual or body corporate. If you leave this section blank, or your named proxy does not attend the meeting, the Chair of the Meeting will be your proxy. A proxy need not be a securityholder of the company. Do not write the name of the issuer company or the registered securityholder in the space.

Appointment of a Second Proxy

You are entitled to appoint up to two proxies to attend the meeting and vote. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by contacting the company's securities registry or you may copy this form.

To appoint a second proxy you must:

(a) complete two Proxy Forms. On each Proxy Form state the percentage of your voting rights or the number of securities applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.

(b) return both forms together in the same envelope.

STEP 2 VOTING DIRECTIONS TO YOUR PROXY

To direct your proxy how to vote, mark one of the boxes opposite each item of business. All your securities will be voted in accordance with such a direction unless you indicate only a portion of securities are to be voted on any item by inserting the percentage or number that you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on a given item, your proxy may vote as he or she chooses. If you mark more than one box on an item for all your securities your vote on that item will be invalid.

Proxy which is a Body Corporate

Where a body corporate is appointed as your proxy, the representative of that body corporate attending the meeting must have provided an "Appointment of Corporate Representative" prior to admission. An Appointment of Corporate Representative form can be obtained from the company's securities registry.

STEP 3 SIGN THE FORM

The form **must** be signed as follows:

Individual: This form is to be signed by the securityholder.

Joint Holding: where the holding is in more than one name, all the securityholders should sign.

Power of Attorney: to sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.

Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form should be signed by that person. **Please indicate the office held by signing in the appropriate place.**

STEP 4 LODGEMENT

Proxy forms (and any Power of Attorney under which it is signed) must be received no later than 48 hours before the commencement of the meeting, therefore by **10.00am (AEDT) on Tuesday, 10 March 2026.** Any Proxy Form received after that time will not be valid for the scheduled meeting.

Proxy forms may be lodged using the enclosed Reply Paid Envelope or:

Online	https://www.votingonline.com.au/oslegm26
By Fax	+ 61 2 9290 9655
By Mail	Boardroom Pty Limited GPO Box 3993, Sydney NSW 2001 Australia
In Person	Boardroom Pty Limited Level 8, 210 George Street Sydney NSW 2000 Australia

Attending the Meeting

If you wish to attend the meeting please bring this form with you to assist registration.

OncoSil Medical Ltd
ACN 113 824 141

☐ **Your Address**
This is your address as it appears on the company's share register. If this is incorrect, please mark the box with an "X" and make the correction in the space to the left. Securityholders sponsored by a broker should advise their broker of any changes.
Please note, you cannot change ownership of your securities using this form.

PROXY FORM

STEP 1 APPOINT A PROXY

I/We being a member/s of **OncoSil Medical Ltd** (Company) and entitled to attend and vote hereby appoint:

☐ the **Chair of the Meeting (mark box)**

OR if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered securityholder) you are appointing as your proxy below

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting as my/our proxy at the Extraordinary General Meeting of the Company to be held **Virtually via link: https://meetings.lumiconnect.com/300-972-839-431 on Thursday, 12 March 2026 at 10.00 (AEDT)** and at any adjournment of that meeting, to act on my/our behalf and to vote in accordance with the following directions or if no directions have been given, as the proxy sees fit.

If I/we have appointed the Chair of the Meeting as my/our proxy or the Chair of the Meeting becomes my/our proxy by default and I/we have not directed my/our proxy how to vote in respect of Resolution 7, I/we expressly authorise the Chair of the Meeting to exercise my/our proxy in respect of this Resolution even though Resolution 7 is connected with the remuneration of a member of the key management personnel for the Company.

The Chair of the Meeting will vote all undirected proxies in favour of all Items of business (including Resolution 7). If you wish to appoint the Chair of the Meeting as your proxy with a direction to vote against, or to abstain from voting on an item, you must provide a direction by marking the 'Against' or 'Abstain' box opposite that resolution..

STEP 2 VOTING DIRECTIONS

* If you mark the Abstain box for a particular item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your vote will not be counted in calculating the required majority if a poll is called.

		For	Against	Abstain*
Resolution 1A	Approval of Issue of Tranche 2 Placement Shares	☐	☐	☐
Resolution 1B	Approval of Issue of Placement Options (Tranche 1 and 2)	☐	☐	☐
Resolution 2	Approval of Issue of Lead Manager Options	☐	☐	☐
Resolution 3	Approval of Director Participation in Placement – Nigel Lange	☐	☐	☐
Resolution 4	Approval of Director Participation in Placement – Thomas Duthy	☐	☐	☐
Resolution 5	Approval of Director Participation in Placement – Lel Smits	☐	☐	☐
Resolution 6	Ratification of Prior Issue of Placement Shares	☐	☐	☐
Resolution 7	Approval of Issue of Remuneration Shares to Nigel Lange in Lieu of Salary	☐	☐	☐

STEP 3 SIGNATURE OF SECURITYHOLDERS

This form must be signed to enable your directions to be implemented.

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name…….. Contact Daytime Telephone……..... Date / / 2026